Inhibitor Therapeutics (INTI) Short Interest Ratio & Short Volume

Short interest is the volume of Inhibitor Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 7,200 shares of INTI short. 0.00% of Inhibitor Therapeutics' shares are currently sold short. Learn More on Inhibitor Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.00% of Inhibitor Therapeutics' floating shares are currently sold short.

Inhibitor Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 7,200 shares, a decrease of 72.1% from the previous total of 25,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.00% of Inhibitor Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Inhibitor Therapeutics: China SXT Pharmaceuticals, Inc. (3.52%), Dyadic International Inc. (0.80%), Allakos Inc. (0.37%), MiNK Therapeutics, Inc. (1.21%), Rani Therapeutics Holdings, Inc. (13.65%), IntelGenx Technologies Corp. (0.01%), SCYNEXIS, Inc. (1.74%), Ayr Wellness Inc. (1.36%), FibroBiologics Inc. (4.21%), KALA BIO, Inc. (5.71%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($29.20 billion), MicroStrategy Incorporated ($10.88 billion), iShares 20+ Year Treasury Bond ETF ($10.04 billion), Capital One Financial Corporation ($5.51 billion), Charter Communications, Inc. ($5.00 billion), Super Micro Computer, Inc. ($4.43 billion), Apollo Global Management Inc. ($4.02 billion), Hims & Hers Health, Inc. ($3.65 billion), VanEck Semiconductor ETF ($3.27 billion), and Coinbase Global, Inc. ($3.10 billion). View all of the most shorted stocks.

Short selling INTI is an investing strategy that aims to generate trading profit from Inhibitor Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Inhibitor Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of INTI, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including INTI, twice per month. The most recent reporting period available is May, 15 2025.